• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SAAM II与PC/WinNonlin建模软件的药代动力学/药效学比较。

A pharmacokinetic/pharmacodynamic comparison of SAAM II and PC/WinNonlin modeling software.

作者信息

Heatherington A C, Vicini P, Golde H

机构信息

Resource Facility for Population Kinetics, Department of Bioengineering, University of Washington, Box 352255, Seattle, Washington 98195-2255, USA.

出版信息

J Pharm Sci. 1998 Oct;87(10):1255-63. doi: 10.1021/js9603562.

DOI:10.1021/js9603562
PMID:9758686
Abstract

This paper presents a detailed comparison of the kinetic analysis software packages SAAM II and PCNonlin/WinNonlin, based on benchmark modeling problems reported in "Pharmacokinetic andPharmacodynamic Data Analysis: Concepts and Applications" (Gabrielsson and Weiner, 1994) and seven additional models. For each model, both software packages were presented with identical implementations. Models were initially executed in PCNonlin or WinNonlin and automated comparisons with SAAM II made using Microsoft Test. Models investigated included one- and multicompartment models with nonlinearities, multiple inputs and samples, multiple simultaneous experiments, and linear equations. Maximum number of compartments, data sets, and parameters were 9, 5, and 10, respectively. We compared 88 different models, many of them in different configurations, e.g., different weighting schemes or different parameter limits. The total number of attempted comparisons between SAAM II and PCNonlin was 161, of which 142 executed without problems. Parameter estimates, their precision (standard errors), and model predictions were compared; a difference of 1% or less was considered "agreement". Observed differences, mainly in parameter standard errors, can be accounted for in terms of different optimization algorithms, convergence criteria, and individual capabilities. In general, there was good agreement (<1% difference) between SAAM II and PCNonlin in terms of parameter estimates and model predictions. However, due to differences in the optimization procedure, parameter standard errors showed considerable differences. Additionally, there were differences when multiple data sets were fitted, indicating the importance of different fitting procedures for interpreting multiple kinetic data sets. The full results of the comparison and the model files in SAAM II and PCNonlin/WinNonlin formats are available from the authors.

摘要

本文基于《药代动力学和药效学数据分析:概念与应用》(加布里埃尔松和维纳,1994年)中报告的基准建模问题以及另外七个模型,对动力学分析软件包SAAM II和PCNonlin/WinNonlin进行了详细比较。对于每个模型,两个软件包都采用相同的实现方式。模型最初在PCNonlin或WinNonlin中执行,并使用Microsoft Test与SAAM II进行自动比较。研究的模型包括具有非线性、多个输入和样本、多个同步实验以及线性方程的单室和多室模型。隔室、数据集和参数的最大数量分别为9、5和10。我们比较了88个不同的模型,其中许多模型具有不同的配置,例如不同的加权方案或不同的参数限制。SAAM II和PCNonlin之间尝试比较的总数为161次,其中142次顺利执行。对参数估计值、其精度(标准误差)和模型预测进行了比较;差异在1%或以下被视为“一致”。观察到的差异主要体现在参数标准误差方面,可以从不同的优化算法、收敛标准和各自的功能方面进行解释。总体而言,SAAM II和PCNonlin在参数估计和模型预测方面具有良好的一致性(差异<1%)。然而,由于优化过程的差异,参数标准误差显示出相当大的差异。此外,在拟合多个数据集时也存在差异,这表明不同的拟合程序对于解释多个动力学数据集的重要性。比较的完整结果以及SAAM II和PCNonlin/WinNonlin格式的模型文件可从作者处获取。

相似文献

1
A pharmacokinetic/pharmacodynamic comparison of SAAM II and PC/WinNonlin modeling software.SAAM II与PC/WinNonlin建模软件的药代动力学/药效学比较。
J Pharm Sci. 1998 Oct;87(10):1255-63. doi: 10.1021/js9603562.
2
Pk-fit: a pharmacokinetic/pharmacodynamic and statistical data analysis software.Pk-fit:一款药代动力学/药效学及统计数据分析软件。
Comput Biomed Res. 2000 Oct;33(5):315-29. doi: 10.1006/cbmr.2000.1548.
3
Discrepancies in pharmacokinetic analysis results obtained by using two standard population pharmacokinetics software programs.使用两个标准的群体药代动力学软件程序获得的药代动力学分析结果存在差异。
Fundam Clin Pharmacol. 2009 Feb;23(1):53-7. doi: 10.1111/j.1472-8206.2008.00641.x.
4
SAAM II: A general mathematical modeling rapid prototyping environment.SAAM II:一种通用的数学建模快速原型环境。
CPT Pharmacometrics Syst Pharmacol. 2024 Jul;13(7):1088-1102. doi: 10.1002/psp4.13181. Epub 2024 Jun 11.
5
Generalization of map estimation in SAAM II: validation against ADAPT II in a glucose model case study.SAAM II中地图估计的推广:在葡萄糖模型案例研究中与ADAPT II进行对比验证。
Ann Biomed Eng. 2002 Jul-Aug;30(7):961-8. doi: 10.1114/1.1507328.
6
MATLAB-implemented estimation procedure for model-based assessment of hepatic insulin degradation from standard intravenous glucose tolerance test data.基于 MATLAB 的模型评估方法,从标准静脉葡萄糖耐量试验数据中估算肝胰岛素降解。
Comput Methods Programs Biomed. 2013 May;110(2):215-25. doi: 10.1016/j.cmpb.2012.10.007. Epub 2012 Oct 31.
7
PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel.PKSolver:一个在 Microsoft Excel 中进行药代动力学和药效动力学数据分析的插件程序。
Comput Methods Programs Biomed. 2010 Sep;99(3):306-14. doi: 10.1016/j.cmpb.2010.01.007. Epub 2010 Feb 21.
8
A resource facility for kinetic analysis: modeling using the SAAM computer programs.动力学分析的资源工具:使用SAAM计算机程序进行建模
Health Phys. 1989;57 Suppl 1:457-66. doi: 10.1097/00004032-198907001-00063.
9
An implementation of the Expectation-Maximisation (EM) algorithm for population pharmacokinetic-pharmacodynamic modelling in ACSLXTREME.一种用于ACSLXTREME中群体药代动力学-药效学建模的期望最大化(EM)算法的实现。
Comput Methods Programs Biomed. 2009 Oct;96(1):49-62. doi: 10.1016/j.cmpb.2009.03.011. Epub 2009 May 1.
10
SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies.SAAM II:用于示踪剂和药代动力学研究的模拟、分析与建模软件。
Metabolism. 1998 Apr;47(4):484-92. doi: 10.1016/s0026-0495(98)90064-6.

引用本文的文献

1
SAAM II: A general mathematical modeling rapid prototyping environment.SAAM II:一种通用的数学建模快速原型环境。
CPT Pharmacometrics Syst Pharmacol. 2024 Jul;13(7):1088-1102. doi: 10.1002/psp4.13181. Epub 2024 Jun 11.
2
Assessment of Pharmacokinetic Effects of Herbal Medicines on Escitalopram.草药对艾司西酞普兰药代动力学影响的评估。
Ther Clin Risk Manag. 2024 Feb 26;20:151-160. doi: 10.2147/TCRM.S448090. eCollection 2024.
3
CYP3A5*3 and SLCO1B1 c.521T>C Polymorphisms Influence the Pharmacokinetics of Atorvastatin and 2-Hydroxy Atorvastatin.
CYP3A5*3和SLCO1B1基因c.521T>C多态性影响阿托伐他汀和2-羟基阿托伐他汀的药代动力学。
Pharmaceutics. 2022 Jul 18;14(7):1491. doi: 10.3390/pharmaceutics14071491.
4
Small interfering RNA delivery to the neurons near the amyloid plaques for improved treatment of Alzheimer׳s disease.将小分子干扰RNA递送至淀粉样斑块附近的神经元以改善阿尔茨海默病的治疗。
Acta Pharm Sin B. 2019 May;9(3):590-603. doi: 10.1016/j.apsb.2018.12.010. Epub 2018 Dec 30.
5
A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study.一项II期试点试验,旨在诱导性血液期疟疾感染研究中评估非诺喹对抗早期恶性疟原虫的安全性和有效性。
Malar J. 2016 Sep 13;15(1):469. doi: 10.1186/s12936-016-1511-3.
6
Maternal Pharmacokinetics and Fetal Disposition of (±)-Citalopram during Mouse Pregnancy.小鼠孕期(±)-西酞普兰的母体药代动力学及胎儿分布情况
ACS Chem Neurosci. 2016 Mar 16;7(3):327-38. doi: 10.1021/acschemneuro.5b00287. Epub 2016 Jan 30.
7
The role of patient-based treatment planning in peptide receptor radionuclide therapy.基于患者的治疗计划在肽受体放射性核素治疗中的作用。
Eur J Nucl Med Mol Imaging. 2016 May;43(5):871-880. doi: 10.1007/s00259-015-3248-6. Epub 2015 Nov 18.
8
Efficacy, pharmacokinetics, safety, and tolerability of Flebogamma 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency.在原发性免疫缺陷中,高纯度人静脉用免疫球蛋白 Flebogamma 10% DIF 的疗效、药代动力学、安全性和耐受性。
J Clin Immunol. 2010 Mar;30(2):321-9. doi: 10.1007/s10875-009-9348-y. Epub 2009 Dec 8.
9
Estimation of the 18F-FDG input function in mice by use of dynamic small-animal PET and minimal blood sample data.利用动态小动物正电子发射断层扫描(PET)和最少血液样本数据估算小鼠的18F-氟代脱氧葡萄糖(FDG)输入函数
J Nucl Med. 2007 Dec;48(12):2037-45. doi: 10.2967/jnumed.107.041061. Epub 2007 Nov 15.
10
A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma.一项多中心、前瞻性、开放标签、历史对照临床试验,旨在评估新一代Flebogamma 5%DIF在原发性免疫缺陷疾病(PID)患者中的疗效和安全性。
J Clin Immunol. 2007 Nov;27(6):628-33. doi: 10.1007/s10875-007-9107-x. Epub 2007 Oct 2.